Jpmorgan Chase & CO Fibrogen Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Fibrogen Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 567 shares of FGEN stock, worth $317. This represents 0.0% of its overall portfolio holdings.
Number of Shares
567
Previous 1,673,555
99.97%
Holding current value
$317
Previous $669,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding FGEN
# of Institutions
79Shares Held
37.4MCall Options Held
351KPut Options Held
105K-
Armistice Capital, LLC New York, NY6.8MShares$3.81 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.88MShares$3.29 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA4.62MShares$2.59 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.91MShares$2.19 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.41MShares$1.35 Million0.0% of portfolio
About FIBROGEN INC
- Ticker FGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,741,200
- Market Cap $52.5M
- Description
- FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...